Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
05/21/2012 | 08:45pm CET
   By Peter Loftus 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.94% 63.18 Delayed Quote.10.71%
JOHNSON & JOHNSON 0.47% 133.68 Delayed Quote.-4.77%
MERCK AND COMPANY 0.76% 55.67 Delayed Quote.-1.07%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04:55aJOHNSON & JOHNSON : Greenpeace says brands refusing to reveal palm oil sources
03/17JOHNSON & JOHNSON : FDA Breakthrough Therapy Designation for Erdafitinib in the ..
03/17JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : J&J nears diabetes device exit with $2.1 bln LifeScan sale
03/16JOHNSON & JOHNSON : nears diabetes device exit with $2.1 billion LifeScan sale
03/16JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/16JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/16JOHNSON & JOHNSON : Mylan propose ways to cut TB drugs prices in India
03/15JOHNSON & JOHNSON : - New Late-Breaking Study Finds Wearable Electrocardiogram M..
More news
News from SeekingAlpha
08:03aGeron up 35% premarket on rosier outlook for imetelstat 
04:25aTrump to release opioid epidemic plan 
03/18Basic Guide To Successful Investing - Part I 
03/183 THINGS IN BIOTECH, MARCH 17 : Janssen's Bladder Breakthrough, MorphoSys' Alzhe.. 
03/17JOHNSON & JOHNSON : A Dividend King For Strong Returns 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,70%
P/E ratio 2018 18,56
P/E ratio 2019 17,42
EV / Sales 2018 4,57x
EV / Sales 2019 4,23x
Capitalization 359 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 12%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965
AMGEN8.25%136 727